Overcoming resistance to anti-EGFR antibody therapy in colorectal cancer using novel targeted PI3K and MEK inhibitors [ 2013 - 2015 ]

Research Grant

Researchers: A/Pr Oliver Sieber (Principal investigator) ,  Dr Jayesh Desai ,  Prof John Mariadason

Brief description Cetuximab treatment is a standard of care for metastatic colorectal cancer, but patients with KRAS, BRAF, PIK3CA or PTEN gene mutated tumours show a lack of response. Newly developed targeted inhibitors against PI3K and MEK may overcome cetuximab resistance. We will perform preclinical studies in cell lines representing the range of mutated tumours found in patients to compare the efficacy of these novel treatments with cetuximab and to characterise the mechanisms underlying drug action.

Funding Amount $AUD 466,586.83

Funding Scheme Project Grants

Notes Standard Project Grant